Learning outcomes
By the end of this lesson you should be able to: define amyloid and state its universal physical property; link the chemical classification of amyloid to the clinical syndromes; predict the organ consequences of systemic deposition from the physics of a stiff protein gel; list the sites used for diagnosis and explain the role of tissue biopsy with Congo red staining; and outline the treatment targets for the major systemic forms.
Prerequisites
Lessons 1-13 of this course, especially lesson 4 (chronic inflammation, because reactive amyloidosis follows chronic inflammatory disease) and lesson 10 (the plasma cell dyscrasias that produce the light-chain form). The chemistry of protein misfolding in BCHM 101 underpins the definition.
The big idea
Every amyloid deposit is made of three components: the main fibril protein, a serum amyloid P component, and glycosaminoglycans. The pool of fibril protein differs by cause, but the shared beta-pleated structure is what makes all amyloid behave alike — this is why amyloid in heart, kidney or tongue looks identical under the microscope and stains Congo red in the same way, whatever protein went into it. Fifteen or so fibril proteins are recognised, and the clinical course is decided by which one it is, not merely by where it is deposited. The tissue never dies of the deposit mechanically; it dies of the space the deposit takes up and the function it displaces.
The chemical classification
| Type | Fibril protein | Source and setting |
|---|---|---|
| AL (primary systemic) | Immunoglobulin light chains | Plasma cell dyscrasia — multiple myeloma and the light-chain–secreting lymphomas; the commonest form in clinical practice |
| AA (secondary/reactive) | Serum amyloid A | Chronic inflammatory disease — tuberculosis, bronchiectasis, rheumatoid arthritis, inflammatory bowel disease, chronic osteomyelitis, familial Mediterranean fever |
| Hereditary ATTR (familial amyloid neuropathy) | Mutant transthyretin | Inherited mutations of transthyretin (the transport protein for thyroxine and retinol) producing mixed neuropathy and cardiomyopathy |
| Wild-type ATTR (senile systemic) | Normal transthyretin | The elderly patient with restrictive cardiomyopathy — increasingly diagnosed in heart failure with preserved ejection fraction |
| Abeta2M (dialysis-associated) | Beta-2 microglobulin | Long-term haemodialysis, the patient on dialysis for a decade or more |
| Localised endocrine | Calcitonin, islet amyloid polypeptide | Medullary thyroid carcinoma (calcitonin); type 2 diabetes (islet amyloid polypeptide in the beta cells) |
| Localised neurological | Beta amyloid | Alzheimer disease — cortical plaques; the cerebral amyloid angiopathy of the elderly bleed |
Watch outAL is not an old person's disease. It is a neoplasm-related plasma cell dyscrasia, and the cardiac form is the most lethal of all. ATTR in an elderly patient with an infiltrating history of peripheral neuropathy and cardiomyopathy is a different disease needing a different drug (tafamidis), and mistaking it for AL — with its own chemotherapy — does direct harm.
Distribution and organ consequences
The heart failure, nephrotic syndrome, macroglossia and the purpura around the eyes are the clinical patterns, and all four are explained by the same physics: the stiff beta-sheeted fibril occupies tissue space, replaces functional cells, thickens and immobilises basement membranes, and makes the capillary walls brittle so they bleed at minor trauma.
| Organ | Consequence | Mechanism |
|---|---|---|
| Kidney | Nephrotic syndrome — proteinuria, hypoalbuminaemia, oedema (the commonest systemic presentation) | Deposition in the glomerular mesangium and capillary walls |
| Heart | Restrictive cardiomyopathy with diastolic dysfunction; conduction block; the presentation of heart failure with preserved ejection fraction | Amyloid infiltrates the myocardium and stiffens the walls without dilatation |
| Liver and spleen | Hepatomegaly; a hard splenomegaly, sometimes with a 'sago' appearance | Deposition in the sinusoidal and sinusoidal-lining spaces |
| Gut and tongue | Macroglossia, dysphagia, malabsorption and weight loss | Deposition in mucosa, muscularis and tongue |
| Peripheral nerves | Carpal tunnel, a painful sensory neuropathy, autonomic failure (postural hypotension, impotence, bowel dysmotility) | Deposition compresses the nerve trunks (carpal tunnel) or destroys the endoneurium |
| Skin | The pinch purpura of the eyelids, papules, plaques and bullae | Amyloid in the dermal vessel walls causes fragility |
| Blood | A bleeding tendency in AL disease | Amyloid fibrils adsorb clotting factor X and impair platelet function |
Diagnosis
The diagnosis follows a rule: biopsy a tissue and stain it, then type the fibril by identifying its precursor protein. Lesions are best biopsied where they are easiest to reach: a rectal biopsy or an aspiration of abdominal fat gives an adequate sample in most systemic amyloidosis, and the histology is confirmed by Congo red with apple-green birefringence under polarised light. Once amyloid is found, the type is narrowed by serum and urine protein electrophoresis with immunofixation and free light chain assay (which identifies AL), echocardiography with strain imaging and a technetium pyrophosphate scan (which identifies ATTR without a biopsy), and sometimes laser microdissection with mass spectrometry of the deposited fibril in formalin-fixed tissue.
A 70-year-old with a raised NT-proBNP has a stiff heart on echocardiography, plus a numb and painful foot, carpal tunnel, easy bruising and a large tongue. His free light chains are normal. A technetium pyrophosphate scan shows avid myocardial uptake, and fat-pad biopsy stains negative for light chains. The diagnosis is wild-type transthyretin cardiac amyloidosis — the normal transthyretin protein slowly misfolds and deposits, and the normal free light chains steer the diagnosis away from AL.
Treatment
Therapy is aimed at the fibril precursor rather than at the deposit. In AA amyloidosis, control of the chronic inflammatory disease removes the stimulus — colchicine in familial Mediterranean fever is so effective at prevention that it is a lifelong prescription for affected patients. In AL, the treatment is directed at the plasma cell clone with chemotherapy approaches that include high-dose melphalan and autologous stem cell transplantation, and bortezomib-based regimens; support of the transplanted heart or kidney may follow. In ATTR, tafamidis stabilises the transthyretin tetramer and slows the decline in the cardiac form, and gene-silencing approaches reduce the production of the mutant protein.
Common mistakes
Watch outSaying amyloidosis is a single disease. It is a family of deposition diseases unified only by a microscopic appearance, and the treatment of each is different — suppress inflammation, suppress the clone, or stabilise the transthyretin.
Watch outSaying amyloid only deposits in the kidney. The heart is the most lethal target (and a heart that cannot relax can be as fatal as one that cannot pump), and localised deposits need no systemic disease — Alzheimer plaques and medullary thyroid carcinoma deposits are local.
Watch outSaying an elderly stiff heart is 'just hypertensive'. In the elderly patient with heart failure with preserved ejection fraction, wild-type ATTR is an important diagnosis to consider, and the Congo red or the technetium scan, not an assumption, settles it.
Check your understanding
What do all amyloid fibrils have in common, whatever protein they are made of, and how is this detected?
Why does cardiac amyloidosis cause heart failure with a heart of normal size and preserved ejection fraction?
Which chronic inflammatory disease is most classically associated with AA amyloidosis, and how is the amyloid prevented?
Multiple choice
A 70-year-old presents with a nephrotic syndrome, macroglossia and periorbital purpura. What is the most likely amyloid type?
Which finding on tissue examination confirms amyloid?
Which patient most likely has wild-type transthyretin amyloidosis?
Which treatment mechanism most directly reduces the supply of the fibril protein in AA amyloidosis?
Which organ manifestation makes amyloidosis fatal fastest in AL disease?
Summary and next
Amyloidosis is a deposition family, not a single disease: misfolded proteins share one microscopic identity but originate from light chains, acute-phase precursors, transthyretin or beta-2 microglobulin. The consequences follow from the location — nephrotic kidney, stiff heart, bulky tongue, brittle capillaries. Diagnosis is a tissue stained with Congo red plus typing of the fibril precursor, and each type has a distinct treatment: treat the inflammation, the plasma cell clone or the transthyretin.
Next: the cardiovascular system — the most common systemic target for the processes you have studied in this course, from atherosclerosis through infarction to the vasculitides and aneurysms.